Dual bispecific combo cuts myeloma progression risk by 89%

The investigational combination of Tecvayli (teclistamab-cqyv) and Talvey (talquetamab-tgvs) significantly improved outcomes in adults with relapsed or refractory multiple myeloma who had received 1 to 4 prior therapies, according to topline results from the phase 3 MonumenTAL-6 trial.

Compared with investigator-selected standard regimens, the dual bispecific combination reduced the risk of disease progression or death by 89% and the risk of death by 62%. A second investigational arm combining Talvey with pomalidomide reduced progression or death risk by 73%.

The findings could be practice-impacting because they support simultaneously targeting BCMA and GPRC5D earlier in the disease course—potentially offering a readily available alternative to personalized cellular therapies while producing deep, durable disease control. Both investigational arms met the primary progression-free survival endpoint, prompting an independent monitoring committee to recommend unblinding at the first interim analysis.

Safety was reportedly consistent with the known profiles of the individual agents. However, detailed efficacy and adverse-event data have not yet been presented, and the combination remains investigational.

Source: Johnson & Johnson. (2026 July 23). TECVAYLI + TALVEY reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma